High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients

Circulation

Volumn 110, Issue 3, 2004, Pages 285-291

  Cai, Weijing ^a   He, John Cijiang ^a   Zhu, Li ^a   Peppa, Melpomeni ^a   Lu, Changyong ^a   Uribarri, Jaime ^a   Vlassara, Helen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Diabetes; Endothelium; Glycation; Glycotoxins; Kinases

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; ENZYME ACTIVATOR; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MICROTUBULE ASSOCIATED PROTEIN 1; MICROTUBULE ASSOCIATED PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ADULT; AGED; ARTICLE; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DIET RESTRICTION; DIETARY INTAKE; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; GLYCATION; GLYCOXIDATION; HIGH ADVANCED GLYCATION END PRODUCT DIET; HUMAN; HUMAN CELL; MALE; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; TIME; TOXICITY; VASCULAR TOXICITY;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NADPH OXIDASE; NF-KAPPA B; OXIDATION-REDUCTION; TRANS-ACTIVATION (GENETICS); VASCULAR CELL ADHESION MOLECULE-1;

EID: 3242700397     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000135587.92455.0D     Document Type: Article

References (35)

1. Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med. 1991;90:56S-61S.
2. Stary HC, Bleakley Chandler A, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb. 1994;14:840-856.
3. Lyons TJ, Jenkins AJ. Lipoprotein glycation and its metabolic consequence. Curr Opin Lipidol. 1997;8:174-180.
4. waf. J Clin Invest. 2002;109:111-119.
5. Tsai EC, Hirsch IB, Brunzell JD, et al. Reduced plasma peroxy radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes. 1994;43:1010-1014.
6. Rabini RA, Cester N, Staffolani R, et al. Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes. 1999;48:2221-2228.
7. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A. 1994;91:9441-9445.
8. Fu MX, Requena JR, Jenkins AJ, et al. The advanced glycation end product, Nε-(carboxymethyl)lysine is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 1996;271:9982-9986.
9. Al-Abed Y, Liebich H, Voelter W, et al. Hydroxyalkenal formation induced by advanced glycosylation of low density lipoprotein. J Biol Chen. 1996;271:2892-2896.
10. Velarde V, Jenkins A, Christopher J, et al. Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells. J Appl Physiol. 2001;91:1412-1420.
11. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev. 2001;17:436-443.
12. Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-97.
13. Lander HL, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation endproducts triggers a MAP kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810-17814.
14. Kusuhara M, Chait A, Cader A, et al. Oxidized LDL stimulates mitogen-activated protein kinase in smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 1997;17:141-148.
15. Collins T, Cybulsky MI. NF-κB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001;107:255-264.
16. O'Brien J. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr. 1989;28:211-248.
17. Koschinsky T, He C, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy Proc Natl Acad Sci U S A. 1997;94:6474-6479.
18. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596-15601.
19. Lin RY, Reis ED, Dore AT, et al. Lowing of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002;163:303-311.
20. Lin RY, Choudhury R, Lu M, et al. Suppression of atherosclerotic lesions by dietary restriction of advanced glycation end products (AGEs) in diabetic apolipoprotein E-deficient C57BL/6J mice. Atherosclerosis. 2003;168:213-220.
21. Liu J, Razani B, Tang S, et al. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells: angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J Biol Chem. 1999;274:15781-15785.
22. Escargueil-Blanc I, Andrieu-Abadie N, Caspar-Bauguil S, et al. Apoptosis and activation of the sphingomyelin-ceramide pathway induced by oxidized low density lipoproteins are not causally related in ECV-304 endothelial cells. J Biol Chem. 1998;273:27389-27395.
23. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Circulation. 1994;89:1333-1445.
24. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care. 2001;24(suppl 1):S44-S47.
25. Mitsuhashi T, Vlassara H, Founds HW, et al. Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J Immunol Methods. 1997;207:79-88.
26. 2a from low density lipoprotein during its in vitro oxidation. Prostaglandins Leukot Essent Fatty Acids. 2000;62:217-224.
27. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endoproducts interacting with their endothelial receptor induced expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J Clin Invest. 1995;96:1395-1403.
28. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins markedly reduces AGE toxins in renal failure patients. J Am Soc Nephrol. 2003;14:728-731.
29. Zheng F, He C, Cai W, et al. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev. 2002;18:224-237.
30. Treins C, Giorgetti-Peraldi S, Murdaca J, et al. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem. 2001;276:43836-43841.
31. Griendling KK, Sorescu D, Lassegue B, et al. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000;20:2175-2183.
32. Cai W, Cao Q, Zhu L, et al. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8:337-346.
33. Stitt AW, He C, Friedman S, et al. Elevated AGE-modified apoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relation to tissue AGE. Mol Med. 1997;3:617-627.
34. Adams MR, Kinlay S, Blak GJ, et al. Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic syndrome. Annu Rev Med. 2000;51:149-167.
35. Sakata N, Uesugi N, Takebayashi S, et al. Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis. Cardiovasc Res. 2001;49:466-475.